Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galderma Jumps Into Dermal Filler Device Market With Q-Med Offer

This article was originally published in The Gray Sheet

Executive Summary

Dermatology drug maker Galderma will be able to offer Q-Med’s Restylane dermal filler device alongside its Azzalure botulinum toxin for wrinkle treatment after acquiring Q-Med for up to $1.1 billion.

You may also be interested in...



Valeant Gains Medicis Through $2.6 Billion Acquisition

The deal is mostly pharmaceutical focused, but Medicis sells several injectable dermal filler devices, including Restylane and Perlane.

FDA Panel Strongly Endorses Oceana's Solesta Fecal Incontinence Product

An FDA advisory panel offered strong support Dec. 2 to Ocean Therapeutics' effort to win PMA approval for its Solesta injectable bulking agent for fecal incontinence.

Merz Pharma Gains Radiesse Dermal Filler Via $253 Mil. BioForm Acquisition

Merz Pharma Group will round out its aesthetic product offerings by adding the Radiesse wrinkle filler device through its $253 million acquisition of BioForm Medical, announced Jan. 4

Topics

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel